NO332625B1 - EP4 agonist forbindelser. - Google Patents

EP4 agonist forbindelser. Download PDF

Info

Publication number
NO332625B1
NO332625B1 NO20040331A NO20040331A NO332625B1 NO 332625 B1 NO332625 B1 NO 332625B1 NO 20040331 A NO20040331 A NO 20040331A NO 20040331 A NO20040331 A NO 20040331A NO 332625 B1 NO332625 B1 NO 332625B1
Authority
NO
Norway
Prior art keywords
oxo
hydroxy
azaprost
tetranor
thia
Prior art date
Application number
NO20040331A
Other languages
English (en)
Norwegian (no)
Other versions
NO20040331L (no
Inventor
Akio Nishiura
Kaoru Kobayashi
Toru Maruyama
Takayuki Maruyama
Tohru Kambe
Hideyuki Yoshida
Nobutaka Abe
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20040331L publication Critical patent/NO20040331L/no
Publication of NO332625B1 publication Critical patent/NO332625B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
NO20040331A 2001-07-23 2004-01-23 EP4 agonist forbindelser. NO332625B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001222148 2001-07-23
JP2001239895 2001-08-07
JP2002056449 2002-03-01
PCT/JP2002/007385 WO2003009872A1 (en) 2001-07-23 2002-07-22 Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient

Publications (2)

Publication Number Publication Date
NO20040331L NO20040331L (no) 2004-03-23
NO332625B1 true NO332625B1 (no) 2012-11-19

Family

ID=27347210

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20040331A NO332625B1 (no) 2001-07-23 2004-01-23 EP4 agonist forbindelser.
NO20111765A NO20111765L (no) 2001-07-23 2011-12-22 Legemidler for sykdommer med benmassetap som har EP4 agonist som den aktive bestanddel

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20111765A NO20111765L (no) 2001-07-23 2011-12-22 Legemidler for sykdommer med benmassetap som har EP4 agonist som den aktive bestanddel

Country Status (22)

Country Link
US (3) US7608637B2 (zh)
EP (2) EP2255829A3 (zh)
JP (3) JP4273407B2 (zh)
KR (3) KR20070087078A (zh)
CN (1) CN101921220B (zh)
AT (1) ATE500218T1 (zh)
AU (1) AU2002318759C1 (zh)
BR (1) BR0211364A (zh)
CA (1) CA2454584C (zh)
DE (1) DE60239343D1 (zh)
DK (1) DK1417975T3 (zh)
HU (1) HU230421B1 (zh)
IL (1) IL159996A0 (zh)
MX (1) MXPA04000757A (zh)
NO (2) NO332625B1 (zh)
NZ (1) NZ530885A (zh)
PL (1) PL367740A1 (zh)
PT (1) PT1417975E (zh)
RU (1) RU2303451C2 (zh)
TW (1) TWI313608B (zh)
WO (1) WO2003009872A1 (zh)
ZA (1) ZA200400493B (zh)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
TWI313608B (en) * 2001-07-23 2009-08-21 Ono Pharmaceutical Co Lower bone mass treating agent containing er4 agonist as active ingredient
US20040204590A1 (en) * 2001-12-03 2004-10-14 Ogidigben Miller J. Ep4 receptor agonist, compositions and methods thereof
MXPA04008596A (es) 2002-03-05 2004-12-06 Ono Pharmaceutical Co Compuestos derivados de 8-azaprostaglandina y farmacos que contienen los compuestos como ingrediente activo.
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
JP2005534653A (ja) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
AU2003237520B2 (en) 2002-06-10 2009-01-08 Laboratoires Serono Sa Gamma lactams as prostaglandin agonists and use thereof
EP1545517A1 (en) * 2002-08-28 2005-06-29 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
WO2004037786A2 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. 2-pyrrolidones as ep4 receptor agonists
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7256211B1 (en) * 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
JP5023492B2 (ja) * 2003-12-05 2012-09-12 小野薬品工業株式会社 馬尾神経組織血流増加剤
WO2005072743A1 (ja) * 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
US20080234337A1 (en) * 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
EP1782830A4 (en) * 2004-08-10 2009-07-29 Ono Pharmaceutical Co PREVENTION AND / OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING AN EP4 AGONIST
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
AU2005299473B2 (en) * 2004-10-26 2012-06-28 Allergan, Inc. Therapeutic and delivery methods of prostaglandin EP4 agonists
CA2586752A1 (en) 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
CA2587318A1 (en) 2004-12-06 2006-06-15 Laboratoires Serono S.A. Pyrrolidin-2-one derivatives for use as dp1 receptor agonists
JPWO2006118173A1 (ja) 2005-04-28 2008-12-18 小野薬品工業株式会社 経皮吸収製剤
EP1886693A4 (en) * 2005-06-03 2010-03-03 Ono Pharmaceutical Co ACTIVE AGENT FOR REGENERATING AND / OR PROTECTING NERVES
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US7491844B2 (en) * 2006-05-04 2009-02-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7476755B2 (en) * 2006-05-04 2009-01-13 Allergan, Inc. Therapeutic compounds
EP2085088A4 (en) * 2006-10-26 2012-08-29 Ono Pharmaceutical Co ADHESIVE PREPARATION
EP2094273B1 (en) 2006-11-16 2013-03-06 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
JP5479092B2 (ja) 2007-05-08 2014-04-23 国立大学法人浜松医科大学 Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
WO2010104167A1 (ja) * 2009-03-13 2010-09-16 国立大学法人東京大学 多官能性化合物及びそれを用いて得られるヘテロ原子ポリマーならびにそれらの製造方法
NZ596960A (en) 2009-06-10 2013-04-26 Ono Pharmaceutical Co Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
EP2488168A1 (en) 2009-10-14 2012-08-22 Gemmus Pharma Inc. Combination therapy treatment for viral infections
KR200457847Y1 (ko) * 2010-02-12 2012-01-06 김인주 케이블 정리밴드
RU2013108394A (ru) * 2010-07-30 2014-09-10 Аллерган, Инк. Соединения и способы восстановления кожи
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (en) 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
BR112014002377A2 (pt) 2011-08-02 2017-02-21 Ono Pharmaceutical Co agente intensificador da função diastólica do ventrículo esquerdo
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (en) 2012-02-16 2016-11-02 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
ES2612921T3 (es) 2012-07-19 2017-05-19 Cayman Chemical Company, Incorporated Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
RU2503458C1 (ru) * 2012-08-27 2014-01-10 Сергей Васильевич Чуйкин Способ местного лечения и профилактики основных стоматологических заболеваний у детей с хронической почечной недостаточностью с применением жевательного фитосубстрата
PT2891651T (pt) 2012-08-31 2017-05-08 Ono Pharmaceutical Co Sal de amina e cristais do mesmo
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
ES2635635T3 (es) 2013-03-15 2017-10-04 Cayman Chemical Company, Incorporated Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
WO2014144500A2 (en) * 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
CA2910398A1 (en) * 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
KR102446027B1 (ko) 2017-12-25 2022-09-21 아사히 가세이 파마 가부시키가이샤 함질소 6원환 화합물
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (zh) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
JPS503362B1 (zh) 1970-06-10 1975-02-04
US4054736A (en) * 1970-06-10 1977-10-18 Ono Pharmaceutical Co., Ltd. Clathrate compounds of prostaglandins or their analogues with cyclodextrin
JPS5231404B1 (zh) 1971-04-28 1977-08-15
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2556326A1 (de) 1975-12-13 1977-06-23 Hoechst Ag Neue pyrrolidone und verfahren zu ihrer herstellung
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
SE423813B (sv) * 1976-08-06 1982-06-07 Pfizer Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) * 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
WO1999012551A1 (en) 1997-09-09 1999-03-18 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring fp selective agonists
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
JP3703004B2 (ja) * 1998-07-15 2005-10-05 小野薬品工業株式会社 ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
EP1121133A1 (en) * 1998-10-15 2001-08-08 Merck & Co., Inc. Methods for stimulating bone formation
AU1444200A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
US6211226B1 (en) 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
WO2000054808A1 (fr) 1999-03-16 2000-09-21 Toray Industries, Inc. Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
MXPA02006322A (es) 1999-12-22 2002-12-13 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
EP1132086B1 (en) * 2000-01-31 2006-05-31 Pfizer Products Inc. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
AU2001235990A1 (en) 2000-02-28 2001-09-03 Fumie Sato Prostaglandin e derivatives
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
ATE374182T1 (de) * 2000-11-27 2007-10-15 Pfizer Prod Inc Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
AU2002328338C1 (en) * 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
TWI313608B (en) * 2001-07-23 2009-08-21 Ono Pharmaceutical Co Lower bone mass treating agent containing er4 agonist as active ingredient

Also Published As

Publication number Publication date
KR20070043059A (ko) 2007-04-24
JP2009137977A (ja) 2009-06-25
DE60239343D1 (de) 2011-04-14
US8207223B2 (en) 2012-06-26
CA2454584A1 (en) 2003-02-06
EP1417975A4 (en) 2007-08-29
JP2012111767A (ja) 2012-06-14
ATE500218T1 (de) 2011-03-15
PL367740A1 (en) 2005-03-07
CN101921220B (zh) 2013-05-22
JPWO2003009872A1 (ja) 2004-11-11
NZ530885A (en) 2007-09-28
US20050020686A1 (en) 2005-01-27
US7608637B2 (en) 2009-10-27
EP1417975B1 (en) 2011-03-02
KR20040015822A (ko) 2004-02-19
US20100010222A1 (en) 2010-01-14
NO20040331L (no) 2004-03-23
NO20111765L (no) 2004-03-23
DK1417975T3 (da) 2011-04-18
US20120202773A1 (en) 2012-08-09
HUP0600140A2 (en) 2007-08-28
EP1417975A1 (en) 2004-05-12
IL159996A0 (en) 2004-06-20
RU2004105154A (ru) 2005-06-27
RU2303451C2 (ru) 2007-07-27
WO2003009872A1 (en) 2003-02-06
ZA200400493B (en) 2005-03-30
PT1417975E (pt) 2011-05-30
TWI313608B (en) 2009-08-21
JP4273407B2 (ja) 2009-06-03
JP4973650B2 (ja) 2012-07-11
HU230421B1 (hu) 2016-05-30
HUP0600140A3 (en) 2012-09-28
CN101921220A (zh) 2010-12-22
KR20070087078A (ko) 2007-08-27
AU2002318759C1 (en) 2009-03-05
MXPA04000757A (es) 2004-07-08
KR100826866B1 (ko) 2008-05-06
JP5387699B2 (ja) 2014-01-15
CA2454584C (en) 2009-09-22
EP2255829A2 (en) 2010-12-01
EP2255829A3 (en) 2012-03-28
BR0211364A (pt) 2004-07-13
AU2002318759B2 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
NO332625B1 (no) EP4 agonist forbindelser.
EP1586564B1 (en) 8-azaprostaglandin derivatives and medicinal uses thereof
RU2306309C2 (ru) Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
US7576129B2 (en) Carboxylic acid compounds
JP4419368B2 (ja) プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤
US20040235955A1 (en) Remedies for pruritus
ES2360604T3 (es) Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4.
JP2007186424A (ja) 気管支拡張剤
JP2006528154A (ja) プロスタグランジン受容体のモジュレータとしてのヒドラジド誘導体
JP2005104836A (ja) プロスタグランジン誘導体
JP2007186423A (ja) 気管支拡張剤

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees